SEATTLE & BALTIMORE--(BUSINESS WIRE)--June 5, 2006--Targeted Genetics Corporation (Nasdaq:TGEND - News) reported new data from studies designed to enhance the company's ability to develop novel therapeutic products for the treatment of inflammatory arthritis. The data, presented in two abstracts at the American Society of Gene Therapy (ASGT) 2006 Annual Meeting, demonstrate that adeno-associated virus type 2 (AAV2), the delivery vector used in the company's clinical development candidate tgAAC94 supports sustained transgene expression for at least one year following a single intra-articular administration (abstract #983), and abstract #578 describes the potent anti-inflammatory activity achieved using an AAV vector based on an alternate serotype, AAV1. These studies provide important information that may be used to optimize the safety and efficacy of AAV-based therapeutic products for the treatment of inflammatory arthritis and, potentially, other diseases.
